EGFR/KRAS Mutations and Gefitinib Therapy in Chinese NSCLC Patients

Publisher： Karger

E-ISSN： 2296-5262|31|4|174-178

ISSN： 2296-5270

Source： Oncology Research and Treatment, Vol.31, Iss.4, 2008-03, pp. : 174-178

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

EGFR-Blockade mit Gefitinib. Erfolge beim NSCLC

By  

Oncology Research and Treatment, Vol. 27, Iss. 3, 2004-07 ,pp. : 322-323

Karger

Access to resources Recommend Favorite

EGFR mutations detected on cytology samples by a centralized laboratory reliably predict response to gefitinib in non–small cell lung carcinoma patients

By  

CANCER CYTOPATHOLOGY, Vol. 121, Iss. 10, 2013-10 ,pp. : 552-560

John Wiley & Sons Inc

Access to resources Recommend Favorite

Elucidating the prognostic significance of KRAS, NRAS, BRAF and PIK3CA mutations in Chinese patients with metastatic colorectal cancer

By  

ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, Vol. 11, Iss. 2, 2015-06 ,pp. : 160-169

John Wiley & Sons Inc

Access to resources Recommend Favorite

The impact of EGFR mutations on gefitinib sensitivity in non-small cell lung cancer

By Suzuki Takeshi   Mitsudomi Tetsuya   Hida Toyoaki  

Personalized Medicine, Vol. 1, Iss. 1, 2004-12 ,pp. : 27-34

Future Medicine

Access to resources Recommend Favorite

The Role of KRAS Mutations in Predicting the Efficacy of Cetuximab-Plus-Irinotecan Therapy in Irinotecan-Refractory Korean Metastatic Colorectal Cancer Patients

By  

Oncology, Vol. 77, Iss. 3-4, 2009-09 ,pp. : 224-230

Karger

Access to resources Recommend Favorite